Clinical Trial

Safety and Effectiveness Study of Dragonfly System for Degenerative Mitral Regurgitation

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated June 11, 2021 (before its estimated May 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
To confirm the effectiveness and safety of the Dragonfly transcatheter mitral valve repair system for the treatment of symptomatic moderate-to-severe(3+) or severe(4+) degenerative mitral regurgitation (DMR) in high surgical risk subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-02-01.
Status change: Not Yet Recruiting → Enrolling by Invitation 2021-06-09
Trial Details
NCT Number NCT04734756
Lead Sponsor Hangzhou Valgen Medtech Co., Ltd
Conditions Degenerative Mitral Valve Disease
Enrollment 120 participants
Start Date 2021-05-04
Primary Completion 2023-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2021-06-11